Skip to Content

Fosinopril Side Effects

Not all side effects for fosinopril may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to fosinopril: oral tablet

In addition to its needed effects, some unwanted effects may be caused by fosinopril. In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking fosinopril:

Less common
  • Blurred vision
  • chest pain or discomfort
  • chills
  • cold sweats
  • confusion
  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
  • fast, slow, or irregular heartbeat
  • pounding or rapid pulse
  • sweating
  • unusual tiredness or weakness

Some of the side effects that can occur with fosinopril may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Cough
Less common
  • Body aches or pain
  • diarrhea
  • difficult breathing
  • ear congestion
  • fever
  • headache
  • loss of voice
  • muscle or bone pain
  • nasal congestion
  • nausea and vomiting
  • runny nose
  • sneezing
  • sore throat
  • weakness

For Healthcare Professionals

Applies to fosinopril: oral tablet


General side effects including headache (3.2%) have been reported. Other general side effects including fatigue, weakness, weight gain, sensation of cold, fall, pain and excessive sweating have been reported.[Ref]

Nervous system

Nervous system side effects have included dizziness (2% to 12%) and headache (up to 3%). Rare nervous system side effects have included lightheadedness, paresthesia, lightheadedness, fatigue, transient ischemic attacks, cerebral infarction, tinnitus, dysgeusia, and sleep disturbance.[Ref]


Gastrointestinal side effects have occurred in approximately 1% to 2% of patients and have included nausea, general abdominal pain, diarrhea, dysgeusia, and dry mouth. Rare gastrointestinal problems that have been rarely associated with the use of fosinopril have included pancreatitis, dysphagia, abdominal distention, flatulence, constipation, heartburn, and appetite/weight changes.[Ref]


Cardiovascular side effects have most commonly included mild first dose hypotension (2.4%) and orthostatic hypotension (1.4%). Shock (0.2%) has rarely been associated with the use of this drug. Rare cardiovascular problems associated with the use of fosinopril, but without clear causal effect, have included angina, myocardial infarction, cerebrovascular accident, hypertensive crisis, rhythm disturbances, palpitations, flushing, sudden death, cardiorespiratory arrest, conduction disorders, syncope, and claudication.[Ref]


Metabolic effects have included hyperkalemia in 2% of patients and rare reports of gout.[Ref]

Risk factors for the development of hyperkalemia include preexisting renal disease, diabetes mellitus, and the concomitant use of potassium-sparing diuretics.

Data show that total serum cholesterol and lipoprotein A levels are significantly decreased during fosinopril therapy relative to placebo.[Ref]


Respiratory side effects have included an idiosyncratic cough in approximately 2% to 10% of patients. Rare cases of asthma, bronchospasm, tracheobronchitis, abnormal breathing, pleuritic chest pain, abnormal vocalization, pharyngitis, sinusitis/rhinitis and laryngitis/hoarseness have been reported.[Ref]

A rare syndrome of cough, bronchospasm, and eosinophilia is reported in two patients treated with fosinopril.

A retrospective study has revealed a significantly higher incidence of discontinuation of angiotensin converting enzyme inhibitor therapy due to cough among black patients compared to non-black patients (9.6% vs. 2.4%).

Several agents have been studied for treating cough with ACE inhibitors. No long term trials exist to allow a definitive treatment option. Cromolyn has the most data showing some benefit. Other agents studied include baclofen, theophylline, sulindac, and benzonatate.[Ref]


Patients with intestinal angioedema generally present with abdominal pain (with or without nausea or vomiting) and in some cases there was no prior history of facial angioedema, and C-1 esterase levels were normal. These symptoms resolve after stopping the ACE inhibitor.[Ref]

Hypersensitivity reactions to angiotensin converting enzyme (ACE) inhibitors may be life threatening. Angioedema of the face, extremities, lips, tongue, glottis and/or pharynx have been reported rarely in patients receiving ACE inhibitors. In addition, intestinal angioedema has been reported in patients treated with ACE inhibitors. It is recommended that any patient with dyspnea, dysphagia, or significant facial angioedema stop therapy immediately and avoid ACE inhibitor therapy in general.[Ref]


Renal impairment is very rare. Essentially no changes in serum creatinine have been reported except for rare cases associated with fosinopril-induced hypotension. Fosinopril-induced renal insufficiency is more likely in patients with a history of congestive heart failure, preexisting renal insufficiency, renal artery stenosis, sodium or intravascular volume depletion or who are on concurrent antihypertensives.[Ref]


Experts recommend discontinuation of therapy with this drug if jaundice or markedly elevated hepatic serum enzymes develop.[Ref]

Hepatic side effects associated with the use of fosinopril or other ACE inhibitors have included a rare syndrome that begins with cholestatic jaundice and progresses to fulminant hepatic necrosis and sometimes death. Rare hepatic side effects have included hepatomegaly and hepatitis.[Ref]


Genitourinary complaints have included impotence in 1% of male patients. More rare genitourinary complaints have included abnormal urination, kidney pain, renal insufficiency and urinary frequency.[Ref]


Hematologic side effects including lymphadenopathy, decreases in hematocrit, and increases in the blood urea nitrogen, serum creatinine and serum potassium have been reported. Agranulocytosis and neutropenia, which have occurred with other ACE inhibitors, have not been associated with fosinopril. Rare reports of decreased white blood cell counts have been reported.[Ref]


An 83-year-old lady taking fosinopril 20 mg/day was diagnosed with scleroderma six months after beginning fosinopril therapy and a 59-year-old female taking 20 mg/day was diagnosed with eosinophilic fasciitis five months after beginning therapy. Although it can not be proved, the physician felt that the appearance of these illnesses pointed to fosinopril therapy in each case due to (1) both scleroderma and eosinophilic fasciitis are rare disorders, (2) in both cases, the symptoms appeared a few months after therapy initiation with fosinopril, (3) the second patient with eosinophilic fasciitis presented with a cough one month after beginning fosinopril therapy, (4) the onset in both cases was sudden and progressed rapidly; the clinical course stabilized once the fosinopril was discontinued.[Ref]

Immunologic side effects including one case of scleroderma and eosinophilic fasciitis has been reported.[Ref]


Psychiatric symptoms have included memory disturbances, tremor, confusion, behavior and mood changes, and depression.[Ref]


Musculoskeletal side effects have included musculoskeletal pain in approximately 3% of patients. Rarely, arthralgias, myalgias/muscle cramp, swelling of an extremities and weakness of an extremity have been reported.[Ref]


Ocular side effects have included vision disturbance and eye irritation.[Ref]


Dermatological side effects have included urticaria, rash, photosensitivity, and pruritus.[Ref]


1. "Multum Information Services, Inc. Expert Review Panel"

2. "Product Information. Monopril (fosinopril)." Bristol-Myers Squibb, Princeton, NJ.

3. Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996): 55-61

4. Weber MA "Fosinopril: a new generation of angiotensin-converting enzyme inhibitors." J Cardiovasc Pharmacol 20 (1992): s7-12

5. Anderson RJ, Duchin KL, Gore RD, Herman TS, Michaels RS, Nichola PS, Nolen TM, Wolfson P, Wombolt DG, Zusman R "Once-daily fosinopril in the treatment of hypertension." Hypertension 17 (1991): 636-42

6. Wagstaff AJ, Davis R, Mctavish D "Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension." Drugs 51 (1996): 777-91

7. Davis R, Coukell A, McTavish D "Fosinopril: A review of its pharmacology and clinical efficacy in the management of heart failure." Drugs 54 (1997): 103-16

8. Ford NF, Fulmor IE, Nichola PS, Alpin PG, Herron JM "Fosinopril monotherapy: relationship between blood pressure reduction and time of administration." Clin Cardiol 16 (1993): 324-30

9. Antonios TFT, Macgregor GA "Angiotensin converting enzyme inhibitors in hypertension: potential problems." J Hypertens 13 Suppl (1995): s11-6

10. Duchin KL, Waclawski AP, Tu JI, Manning J, Frantz M, Willard DA "Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects." J Clin Pharmacol 31 (1991): 58-64

11. Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yanagawa N "Pharmacokinetics of fosinopril in patients with various degrees of renal function." Clin Pharmacol Ther 49 (1991): 457-67

12. Oren S, Messerli FH, Grossman E, Garavaglia GE, Frohlich ED "Immediate and short-term cardiovascular effects of fosinopril, a new angiotensin-converting enzyme inhibitor, in patients with essential hypertension." J Am Coll Cardiol 17 (1991): 1183-7

13. Keilani T, Schlueter WA, Levin ML, Batlle DC "Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor." Ann Intern Med 118 (1993): 246-54

14. Holdaway IM, Gamble GD, Sanders GA, Greaves SC, Ellispegler EM, Sharpe N "Effect of fosinopril on cardiac and metabolic parameters in patients with NIDDM." Diabetes Care 17 (1994): 1476-9

15. Herings RMC, Deboer A, Stricker BHC, Leufkens HGM, Porsius A "Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme." Lancet 345 (1995): 1195-8

16. Schlueter W, Keilani T, Batlle DC "Metabolic effects of converting enzyme inhibitors - focus on the reduction of cholesterol and lipoprotein(a) by fosinopril." Am J Cardiol 72 (1993): H37-44

17. Guthrie R "Fosinopril - an overview." Am J Cardiol 72 (1993): H22-4

18. Germino FW, Lastra J, Pool P, Punzi H, Spinowitz B, Smith W, Wallace S, Willett M, Mills D, Desilva J, Cryer D "Evaluation of the cough profile of fosinopril in hypertensive patients with ace inhibitor-associated cough - a pilot study." Curr Ther Res Clin Exp 54 (1993): 469-75

19. Luque CA, Ortiz MV "Treatment of ACE inhibitor-induced cough." Pharmacotherapy 19 (1999): 804-10

20. Semple PF "Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors." J Hypertens 13 Suppl (1995): s17-21

21. Elliott WJ "Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects." Clin Pharmacol Ther 60 (1996): 582-8

22. Gunkel AR, Thurner KH, Kanonier G, Sprinzl GM, Thumfart WF "Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors." Am J Otolaryngol 17 (1996): 87-91

23. Olivier PB, Germain ML, Carette BD, Millart HG, Trenque TC "Elevation of serum creatinine following fosinopril therapy." Ann Pharmacother 33 (1999): 382-3

24. Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, Frantz M "Disposition of fosinopril sodium in healthy subjects." Br J Clin Pharmacol 25 (1988): 9-15

25. Biasi D, Caramaschi P, Carletto A, Bambara LM "Scleroderma and eosinophilic fasciitis in patients taking fosinopril." J Rheumatol 24 (1997): 1242

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.